Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$81.04 - $134.63
Previous CloseN/A
Volume3.30M
Average Volume (3M)18.19M
Market Cap
$235.20B
Enterprise Value$276.94B
Total Cash (Recent Filing)$13.24B
Total Debt (Recent Filing)$37.11B
Price to Earnings (P/E)13.8
Beta0.23
Next Earnings
Apr 24, 2025EPS Estimate
2.13Last Dividend Ex-Date
Mar 17, 2025Dividend Yield3.35%
Share Statistics
EPS (TTM)6.73
Shares Outstanding2,526,036,100
10 Day Avg. Volume19,715,902
30 Day Avg. Volume18,192,718
Financial Highlights & Ratios
PEG Ratio0.00302
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)17.00
P/FCF Ratio17.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.34
Enterprise Value/Ebitda10.28
Forecast
1Y Price Target
$111.88Price Target Upside21.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Drug EffectivenessThe ZENITH and HYPERION trial updates support the broad benefit of Winrevair in both late and early PAH patients, potentially increasing its uptake.
Earnings OutlookMerck's earnings outlook is accelerating, with net income growth expected to increase significantly.
Product DevelopmentThe subcutaneous option provides greater differentiation relative to the expected IV biosimilars and is likely to experience lesser price and volume erosion compared with the IV format.
Bears Say
Market UncertaintyClarity around Gardasil is not improving, the BD effort seems to have lost momentum, and Keytruda's LOE is nearing.
Patent InfringementMerck’s Keytruda subcutaneous formulation may be at risk of infringing more recent Halozyme Mdase patents.
Revenue ConcernsMerck may face risk of revenue drops if pipeline drugs fail to deliver before the patent expiry of Keytruda in 2028.
---
Ownership Overview
0.05% Insiders
21.43% Mutual Funds
15.85% Other Institutional Investors
41.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $81.04 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $235.20B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 04, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.609 by $0.111.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.35%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.13.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,526,036,100 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $1.72 in its last earnings report, beating expectations of $1.609. Following the earnings report the stock price went down -9.076%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.88 (21.20% Upside)
$111.88 (21.20% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 96%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $141.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.44%
12-Months-Change
Fundamentals
Return on Equity
40.81%
Trailing 12-Months
Asset Growth
9.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Company, Inc. (MRK), also known as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a leading global healthcare company headquartered in Kenilworth, New Jersey. The company operates in the pharmaceuticals sector, focusing on the discovery, development, and distribution of innovative medicines, vaccines, and animal health products. Merck's core products span various therapeutic areas, including oncology, vaccines, infectious diseases, diabetes, cardiovascular health, and animal health solutions.
---
MRK Company Deck
---
MRK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in key areas like oncology and new product launches, but challenges persist with GARDASIL in China and impacts from Medicare Part D redesign. Although the company remains confident in its long-term growth potential, short-term headwinds are acknowledged.Read More>---
MRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$111.88
▲(21.20% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+16.12%
assigned a buy rating 12 months ago
Copying Robyn Karnauskas's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +16.12% per trade.
---